PsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement of its Neuropsychiatric Drug Discovery Platform, Expediting its IND Submission to the FDA
News provided by
Share this article
Share this article
PsyBio or the
Company ), a biotechnology company pioneering the next generation of targeted psychoactive medications, announces today that it has amended its master sponsored agreement with Miami University based in Oxford, Ohio (the
Amended Agreement ) to extend and expand the research efforts of the laboratory of Dr. J. Andrew Jones in the Department of Chemical, Paper, and Biomedical Engineering (the
Jones Lab ), to include additional research efforts of the laboratory of Dr. Matthew McMurray in the Department of Psychology (the
PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors
Mr. Oliver joins PsyBio bringing over 25 years of executive pharmaceutical experience having held various senior positions at Otsuka, Wyeth and Johnson & Johnson
News provided by
Share this article
Share this article
PsyBio or the
Company ), a biotechnology company pioneering the next generation of targeted psychoactive medications, is pleased to announce the appointment of Mr. Bob Oliver to the Company s board of directors (the
Board ), effective immediately. The Company is developing a platform technology that produces tryptamines, such as psilocybin and its intermediates, for intended therapeutic use. Mr. Oliver has extensive experience in launching pharmaceutical products into global markets offering invaluable depth to our team.
PsyBio Completes Reverse Take-Over Transaction Common Shares Expected to Commence Trading on the TSX Venture Exchange Imminently
February 19, 2021 15:17 ET | Source: PsyBio Therapeutics Corp. PsyBio Therapeutics Corp.
Not for distribution to United States newswire services or for release publication,
distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States.
TORONTO, Feb. 19, 2021 (GLOBE NEWSWIRE) PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) (the “
Company”), announces that it has completed its previously announced reverse takeover of PsyBio Therapeutics, Inc. (“
PsyBio”), a biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders (the “
PsyBio Completes Reverse Take-Over Transaction Common Shares Expected to Commence Trading on the TSX Venture Exchange Imminently leaderpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leaderpost.com Daily Mail and Mail on Sunday newspapers.
Webcast Information
To attend the live video webcast, please register or email KCSA Strategic Communications at [email protected].
About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, shareholder communications and social media, with expertise in financial and professional services, technology, healthcare, digital media, cannabis and energy. Since 1969, the Firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The Firm s clients are its best references.
For more information, please visit www.kcsa.com.
SOURCE KCSA Strategic Communications